Background: Human immunodeficiency virus (HIV)-infected individuals are at increased risk of age-associated functional impairment, even with effective antiretroviral therapy (ART). A concurrent characterization of skeletal muscle, physical function, and immune phenotype in aviremic middle-aged HIV-infected adults represents a knowledge gap in prognostic biomarker discovery. Methods: We undertook a prospective observational study of 170 middle-aged, HIV-infected ambulatory men and women with CD4+ T-cell counts of at least 350/µL and undetectable plasma viremia while on effective ART, and uninfected control participants. We measured biomarkers for inflammation and immune activation, fatigue, the Veterans Aging Cohort Study mortality index, and physical function. A subset also received a skeletal muscle biopsy and computed tomography scan. Results: Compared to the uninfected participants, HIV-infected participants displayed increased immune activation (P < .001), inflammation (P = .001), and fatigue (P = .010), and in a regression model adjusting for age and sex displayed deficits in stair-climb power (P < .001), gait speed (P = .036), and predicted metabolic equivalents (P = .019). Skeletal muscle displayed reduced nuclear peroxisome proliferator-activated receptor-γ coactivator 1α-positive myonuclei (P = .006), and increased internalized myonuclei (P < .001) that correlated with immune activation (P = .003) and leukocyte infiltration (P < .001). Internalized myonuclei improved a model for HIV discrimination, increasing the C-statistic from 0.84 to 0.90. Conclusions: Asymptomatic HIV-infected middle-aged adults display atypical skeletal muscle profiles, subclinical deficits in physical function, and persistent inflammation and immune activation. Identifying biomarker profiles for muscle dysregulation and risk for future functional decline in the HIV-infected population will be key to developing and monitoring preventive interventions. Clinical Trials Registration: NCT03011957.
Background: Human immunodeficiency virus (HIV)-infected individuals are at increased risk of age-associated functional impairment, even with effective antiretroviral therapy (ART). A concurrent characterization of skeletal muscle, physical function, and immune phenotype in aviremic middle-aged HIV-infected adults represents a knowledge gap in prognostic biomarker discovery. Methods: We undertook a prospective observational study of 170 middle-aged, HIV-infected ambulatory men and women with CD4+ T-cell counts of at least 350/µL and undetectable plasma viremia while on effective ART, and uninfected control participants. We measured biomarkers for inflammation and immune activation, fatigue, the Veterans Aging Cohort Study mortality index, and physical function. A subset also received a skeletal muscle biopsy and computed tomography scan. Results: Compared to the uninfected participants, HIV-infectedparticipants displayed increased immune activation (P < .001), inflammation (P = .001), and fatigue (P = .010), and in a regression model adjusting for age and sex displayed deficits in stair-climb power (P < .001), gait speed (P = .036), and predicted metabolic equivalents (P = .019). Skeletal muscle displayed reduced nuclear peroxisome proliferator-activated receptor-γ coactivator 1α-positive myonuclei (P = .006), and increased internalized myonuclei (P < .001) that correlated with immune activation (P = .003) and leukocyte infiltration (P < .001). Internalized myonuclei improved a model for HIV discrimination, increasing the C-statistic from 0.84 to 0.90. Conclusions: Asymptomatic HIV-infected middle-aged adults display atypical skeletal muscle profiles, subclinical deficits in physical function, and persistent inflammation and immune activation. Identifying biomarker profiles for muscle dysregulation and risk for future functional decline in the HIV-infected population will be key to developing and monitoring preventive interventions. Clinical Trials Registration: NCT03011957.
Authors: Gerome V Escota; Pragna Patel; John T Brooks; Tim Bush; Lois Conley; Jason Baker; Erna Milunka Kojic; John Hammer; Nur F Önen Journal: AIDS Res Hum Retroviruses Date: 2015-01-20 Impact factor: 2.205
Authors: Bret H Goodpaster; Seok Won Park; Tamara B Harris; Steven B Kritchevsky; Michael Nevitt; Ann V Schwartz; Eleanor M Simonsick; Frances A Tylavsky; Marjolein Visser; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2006-10 Impact factor: 6.053
Authors: Mark A Wallet; Thomas W Buford; Anna-Maria Joseph; Madhuri Sankuratri; Christiaan Leeuwenburgh; Marco Pahor; Todd Manini; John W Sleasman; Maureen M Goodenow Journal: BMC Immunol Date: 2015-07-24 Impact factor: 3.615
Authors: Mary Clare Masters; Jeremiah Perez; Katherine Tassiopoulos; Adriana Andrade; Ronald Ellis; Jingyan Yang; Todd T Brown; Frank J Palella; Kristine M Erlandson Journal: AIDS Res Hum Retroviruses Date: 2019-09-30 Impact factor: 2.205
Authors: Triin Umbleja; Todd T Brown; Edgar T Overton; Heather J Ribaudo; Jennifer A Schrack; Kathleen V Fitch; Pamela S Douglas; Steven K Grinspoon; Sarah Henn; Roberto C Arduino; Benigno Rodriguez; Constance A Benson; Kristine M Erlandson Journal: J Infect Dis Date: 2020-07-09 Impact factor: 5.226
Authors: Monty Montano; Shalender Bhasin; Richard T D'Aquila; Kristine M Erlandson; William J Evans; Nicholas T Funderburg; Amy Justice; Lishomwa C Ndhlovu; Bisola Ojikutu; Marco Pahor; Savita Pahwa; Alice S Ryan; Jennifer Schrack; Michael B Schultz; Paola Sebastiani; David A Sinclair; Julia Tripp; Bruce Walker; Julie A Womack; Raymond Yung; R Keith Reeves Journal: AIDS Res Hum Retroviruses Date: 2019-09-23 Impact factor: 2.205
Authors: Tom E Robertson; Mehdi Nouraie; Shulin Qin; Kristina A Crothers; Cathy J Kessinger; Deborah McMahon; Divay Chandra; Lawrence A Kingsley; Ruth M Greenblatt; Laurence Huang; Meghan E Fitzpatrick; Alison Morris Journal: PLoS One Date: 2019-04-24 Impact factor: 3.240
Authors: Erin E Sundermann; Kristine M Erlandson; Caitlin N Pope; Anna Rubtsova; Jessica Montoya; Alison A Moore; Catia Marzolini; Kelly K O'Brien; Savita Pahwa; Brendan A I Payne; Leah H Rubin; Sharon Walmsley; Norman J Haughey; Monty Montano; Maile Y Karris; Joseph B Margolick; David J Moore Journal: AIDS Res Hum Retroviruses Date: 2019-09-10 Impact factor: 1.723